{"id":48,"date":"2017-02-02T17:37:45","date_gmt":"2017-02-02T17:37:45","guid":{"rendered":"http:\/\/www.kaigconsulting.com\/?page_id=48"},"modified":"2017-03-13T15:28:04","modified_gmt":"2017-03-13T15:28:04","slug":"who-we-are","status":"publish","type":"page","link":"http:\/\/www.kaigconsulting.com\/?page_id=48","title":{"rendered":"Who We Are"},"content":{"rendered":"<h1><img decoding=\"async\" loading=\"lazy\" class=\"aligncenter wp-image-7 size-thumbnail\" src=\"http:\/\/www.kaigconsulting.com\/wp-content\/uploads\/2017\/01\/Potrait-BW-161016-150x150.jpg\" alt=\"Dr Ian Laws\" width=\"150\" height=\"150\" \/><\/h1>\n<p><strong>KAIG Consulting was established by Dr Ian Laws to provide strategic advice in the areas of medicines development, licensing and business development.<\/strong><\/p>\n<p>With experience at Pfizer, SmithKline Beecham and GSK, Dr Laws has over 25 years successfully lead both a regulatory function and entire drug development programmes across a range of areas of medicine.<\/p>\n<p>He has lived and worked both in Europe and the USA, providing a thorough understanding of both the regulatory environment at FDA and EMA and the different payer and reimbursement systems either side of the Atlantic.\u00a0 In addition, Dr Laws has significant experience of Japanese companies and the local regulatory agency PMDA.<\/p>\n<p>As part of his global experience Dr Laws\u00a0has also\u00a0worked with DIA (US, Europe and\u00a0Japan), TOPRA and PhRMA.<\/p>\n<p>Dr Laws can also offer direct experience of dealing with licensing partners, both large and small from initial Business Development discussions \/ due diligence through to successful partnered drug development and licensing.<\/p>\n<p>&nbsp;<\/p>\n<h1><\/h1>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>KAIG Consulting was established by Dr Ian Laws to provide strategic advice in the areas of medicines development, licensing and business development. With experience at Pfizer, SmithKline Beecham and GSK, Dr Laws has over 25 years successfully lead both a regulatory function and entire drug development programmes across a range [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":59,"menu_order":2,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"aioseo_notices":[],"_links":{"self":[{"href":"http:\/\/www.kaigconsulting.com\/index.php?rest_route=\/wp\/v2\/pages\/48"}],"collection":[{"href":"http:\/\/www.kaigconsulting.com\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"http:\/\/www.kaigconsulting.com\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"http:\/\/www.kaigconsulting.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/www.kaigconsulting.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=48"}],"version-history":[{"count":5,"href":"http:\/\/www.kaigconsulting.com\/index.php?rest_route=\/wp\/v2\/pages\/48\/revisions"}],"predecessor-version":[{"id":90,"href":"http:\/\/www.kaigconsulting.com\/index.php?rest_route=\/wp\/v2\/pages\/48\/revisions\/90"}],"up":[{"embeddable":true,"href":"http:\/\/www.kaigconsulting.com\/index.php?rest_route=\/wp\/v2\/pages\/59"}],"wp:attachment":[{"href":"http:\/\/www.kaigconsulting.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=48"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}